Class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion

PLoS One. 2018 Mar 26;13(3):e0194661. doi: 10.1371/journal.pone.0194661. eCollection 2018.

Abstract

Despite the important role of apolipoprotein E (apoE) secretion from astrocytes in brain lipid metabolism and the strong association of apoE4, one of the human apoE isoforms, with sporadic and late onset forms of Alzheimer's disease (AD) little is known about the regulation of astrocytic apoE. Utilizing annotated chemical libraries and a phenotypic screening strategy that measured apoE secretion from a human astrocytoma cell line, inhibition of pan class I histone deacetylases (HDACs) was identified as a mechanism to increase apoE secretion. Knocking down select HDAC family members alone or in combination revealed that inhibition of the class I HDAC family was responsible for enhancing apoE secretion. Knocking down LXRα and LXRβ genes revealed that the increase in astrocytic apoE in response to HDAC inhibition occurred via an LXR-independent pathway. Collectively, these data suggest that pan class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion.

MeSH terms

  • ATP Binding Cassette Transporter 1 / genetics
  • ATP Binding Cassette Transporter 1 / metabolism
  • Apolipoproteins E / analysis
  • Apolipoproteins E / genetics
  • Apolipoproteins E / metabolism*
  • Astrocytes / cytology
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Cells, Cultured
  • Enzyme-Linked Immunosorbent Assay
  • Genotype
  • Histone Deacetylase Inhibitors / chemistry
  • Histone Deacetylase Inhibitors / pharmacology
  • Histone Deacetylases / chemistry
  • Histone Deacetylases / genetics
  • Histone Deacetylases / metabolism*
  • Humans
  • Hydrocarbons, Fluorinated / pharmacology
  • Liver X Receptors / antagonists & inhibitors
  • Liver X Receptors / genetics
  • Liver X Receptors / metabolism
  • Protein Binding
  • Protein Isoforms / analysis
  • Protein Isoforms / genetics
  • Protein Isoforms / metabolism
  • RNA Interference
  • RNA, Messenger / metabolism
  • RNA, Small Interfering / metabolism
  • Small Molecule Libraries / chemistry
  • Small Molecule Libraries / metabolism
  • Sulfonamides / pharmacology

Substances

  • ATP Binding Cassette Transporter 1
  • Apolipoproteins E
  • Histone Deacetylase Inhibitors
  • Hydrocarbons, Fluorinated
  • Liver X Receptors
  • Protein Isoforms
  • RNA, Messenger
  • RNA, Small Interfering
  • Small Molecule Libraries
  • Sulfonamides
  • T0901317
  • Histone Deacetylases

Grants and funding

The authors did not receive specific funding for this work and are employees of Pfizer Inc. The funder (Pfizer Inc.) provided support in the form of salaries for authors [E.D., J.M.D., F.V., M.B., L.F.L., E.K.S., E.L.C., M.P., K.R.B., G.R.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.